Montelukast modifies simvastatin-induced myopathy and hepatotoxicity

摘要: Montelukast (MNK) has prominent anti-inflammatory and antioxidant activities. It can protect the liver in different hepatotoxic models animals. Simvastatin (SMV) is one of commonly used lipid lowering drugs for treatment dyslipidemia order to reduce cardiovascular disease. severe side effects such as myopathy hepatotoxicity. The aim present study investigate possible effect MNK on SMV-induced Four groups male rats: control group which received saline via stomach tube, treated (received 10 mg/kg/day tube), SMV 30 + (combination) both SMV. All animals were 14 days before obtaining blood tissue samples. myopathy. caused a significant increase myoglobin, creatinine kinase, ALT, AST, ALP, bilirubin but, it decreased total proteins, globulin albumin levels. Co-treatment increased activity significantly. modifies partially myopathic changes Co-administration their toxic potentials liver, skeletal muscles, kidney. They have activities when given together that produce muscle hepatic protective effects.